The latest price target for Caribou Biosciences (NASDAQ:CRBU) was reported by HC Wainwright & Co. on April 7, 2026. The analyst firm set a price target for $9.00 expecting CRBU to rise to within 12 months (a possible 300.89% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Caribou Biosciences (NASDAQ:CRBU) was provided by HC Wainwright & Co., and Caribou Biosciences reiterated their buy rating.

There is no last upgrade for Caribou Biosciences

There is no last downgrade for Caribou Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Caribou Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Caribou Biosciences was filed on April 7, 2026 so you should expect the next rating to be made available sometime around April 7, 2027.

While ratings are subjective and will change, the latest Caribou Biosciences (CRBU) rating was a reiterated with a price target of $9.00 to $9.00. The current price Caribou Biosciences (CRBU) is trading at is $2.25, which is out of the analyst’s predicted range.